Drug intelligence / Profile preview

PMS-001

Development stage: Phase 2
Lead developer: Qingdao Primedicine Pharmaceutical
Modality: Peptides
Administration: Intravenous

Overview

PMS-001 is an investigational peptide biologic being developed by Ruijin Hospital for the treatment of moderate to severe dementia. The drug is currently being evaluated in a Phase 1/2 clinical trial to assess its safety profile and its efficacy in improving long-delay recall in patients with advanced cognitive impairment. Administered via a single-dose intravenous injection, PMS-001 represents a novel peptide-based approach to addressing memory deficits in dementia, although its specific biological target and molecular mechanism of action have not yet been publicly disclosed.

Other names: Peptide PMS-001

Targets

AMPAR (AMPA receptor)

Beyond the preview

Go deeper on PMS-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMS-001.

Explore the full profile